How many years can the targeted drug osimertinib last for patients with advanced lung cancer?

How many years can the targeted drug osimertinib last for late-stage lung cancer is a complex question, and the answer varies depending on individual differences.

Osimertinib has shown significant efficacy in the treatment of certain advanced non-small cell lung cancer (NSCLC). It is an oral multi-target small molecule tyrosine kinase inhibitor that inhibits the growth and spread of tumor cells by inhibiting specific kinase signaling pathways in tumor cells. However, its efficacy and resistance time vary due to individual differences.

The survival time of patients with advanced lung cancer taking osimertinib varies. The minimum time may be about half a year, while the maximum time may be two to three years. This mainly depends on various factors such as individual differences among patients, types of tumor gene mutations, overall health status, and previous treatment options.

After receiving osimertinib treatment, the progression-free survival (PFS) of most patients is approximately 12-19 months. This is the period of time from the start of treatment until the disease progresses or relapses. Clinical studies show that the median progression-free survival of osimertinib is approximately 18 months.

Although osimertinib may be effective in the early stages, tumor cells may gradually develop drug resistance over time. Common resistance mechanisms include T790M mutation, C797S mutation and other genetic changes. After drug resistance occurs, the treatment plan needs to be adjusted according to the specific situation.

In summary, osimertinib can significantly prolong the progression-free survival of patients in the treatment of advanced lung cancer, but the specific maintenance time varies depending on individual differences. While taking osimertinib, patients should receive regular evaluation from their doctor and adjust their treatment plan to deal with possible drug resistance. At the same time, maintaining good living habits and a positive attitude are also important factors in improving treatment effects and survival.